Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

Bernd Gansbacher, Karen Zier, Brian Daniels, Kathy Cronin, Rajat Bannerji, Eli Gilboa

Research output: Contribution to journalArticle

645 Citations (Scopus)

Abstract

To study the effects of localized secretion of cytokines on tumor progression, the gene for human interleukin 2 (IL-2) was introduced via retroviral vectors into CMS-5 cells, a weakly immunogenic mouse fibrosarcoma cell line of BALB/c origin. Secretion of low levels of IL-2 from the tumor cells abrogated their tumorigenicity and induced a long-lasting protective immune response against a challenge with a tumorigenic dose of parental CMS-5 cells. Co-injection of IL-2-producing CMS-5 cells with unmodified tumor cells inhibited tumor formation even when highly tumorigenic doses of CMS-5 cells were used. Cytolytic activity in mice injected with parental CMS-5 cells was transient and was greatly diminished 3 wk after injection, as commonly observed in tumor-bearing animals. However, in mice injected with IL-2-producing cells, tumor-specific cytolytic activity persisted at high levels for the duration of the observation period (at least 75 d). High levels of tumor-specific cytolytic activity could also be detected in parental CMS-5 tumor-bearing animals 18 d after inoculation with tumor cells, if IL-2-producing CMS-5 cells but not unmodified parental tumor cells were used as targets. These studies highlight the potential advantages of localized secretion of cytokines mediated via gene transfer to induce potent anti-tumor immune responses.

Original languageEnglish
Pages (from-to)1217-1224
Number of pages8
JournalJournal of Experimental Medicine
Volume172
Issue number4
StatePublished - Oct 1 1990
Externally publishedYes

Fingerprint

Interleukin-2
Immunity
Genes
Neoplasms
Cytokines
Injections
Fibrosarcoma
Observation
Cell Line

ASJC Scopus subject areas

  • Immunology

Cite this

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. / Gansbacher, Bernd; Zier, Karen; Daniels, Brian; Cronin, Kathy; Bannerji, Rajat; Gilboa, Eli.

In: Journal of Experimental Medicine, Vol. 172, No. 4, 01.10.1990, p. 1217-1224.

Research output: Contribution to journalArticle

Gansbacher, B, Zier, K, Daniels, B, Cronin, K, Bannerji, R & Gilboa, E 1990, 'Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity', Journal of Experimental Medicine, vol. 172, no. 4, pp. 1217-1224.
Gansbacher, Bernd ; Zier, Karen ; Daniels, Brian ; Cronin, Kathy ; Bannerji, Rajat ; Gilboa, Eli. / Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. In: Journal of Experimental Medicine. 1990 ; Vol. 172, No. 4. pp. 1217-1224.
@article{8315fdd78f874b05b30f75321b500cdd,
title = "Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity",
abstract = "To study the effects of localized secretion of cytokines on tumor progression, the gene for human interleukin 2 (IL-2) was introduced via retroviral vectors into CMS-5 cells, a weakly immunogenic mouse fibrosarcoma cell line of BALB/c origin. Secretion of low levels of IL-2 from the tumor cells abrogated their tumorigenicity and induced a long-lasting protective immune response against a challenge with a tumorigenic dose of parental CMS-5 cells. Co-injection of IL-2-producing CMS-5 cells with unmodified tumor cells inhibited tumor formation even when highly tumorigenic doses of CMS-5 cells were used. Cytolytic activity in mice injected with parental CMS-5 cells was transient and was greatly diminished 3 wk after injection, as commonly observed in tumor-bearing animals. However, in mice injected with IL-2-producing cells, tumor-specific cytolytic activity persisted at high levels for the duration of the observation period (at least 75 d). High levels of tumor-specific cytolytic activity could also be detected in parental CMS-5 tumor-bearing animals 18 d after inoculation with tumor cells, if IL-2-producing CMS-5 cells but not unmodified parental tumor cells were used as targets. These studies highlight the potential advantages of localized secretion of cytokines mediated via gene transfer to induce potent anti-tumor immune responses.",
author = "Bernd Gansbacher and Karen Zier and Brian Daniels and Kathy Cronin and Rajat Bannerji and Eli Gilboa",
year = "1990",
month = "10",
day = "1",
language = "English",
volume = "172",
pages = "1217--1224",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "4",

}

TY - JOUR

T1 - Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

AU - Gansbacher, Bernd

AU - Zier, Karen

AU - Daniels, Brian

AU - Cronin, Kathy

AU - Bannerji, Rajat

AU - Gilboa, Eli

PY - 1990/10/1

Y1 - 1990/10/1

N2 - To study the effects of localized secretion of cytokines on tumor progression, the gene for human interleukin 2 (IL-2) was introduced via retroviral vectors into CMS-5 cells, a weakly immunogenic mouse fibrosarcoma cell line of BALB/c origin. Secretion of low levels of IL-2 from the tumor cells abrogated their tumorigenicity and induced a long-lasting protective immune response against a challenge with a tumorigenic dose of parental CMS-5 cells. Co-injection of IL-2-producing CMS-5 cells with unmodified tumor cells inhibited tumor formation even when highly tumorigenic doses of CMS-5 cells were used. Cytolytic activity in mice injected with parental CMS-5 cells was transient and was greatly diminished 3 wk after injection, as commonly observed in tumor-bearing animals. However, in mice injected with IL-2-producing cells, tumor-specific cytolytic activity persisted at high levels for the duration of the observation period (at least 75 d). High levels of tumor-specific cytolytic activity could also be detected in parental CMS-5 tumor-bearing animals 18 d after inoculation with tumor cells, if IL-2-producing CMS-5 cells but not unmodified parental tumor cells were used as targets. These studies highlight the potential advantages of localized secretion of cytokines mediated via gene transfer to induce potent anti-tumor immune responses.

AB - To study the effects of localized secretion of cytokines on tumor progression, the gene for human interleukin 2 (IL-2) was introduced via retroviral vectors into CMS-5 cells, a weakly immunogenic mouse fibrosarcoma cell line of BALB/c origin. Secretion of low levels of IL-2 from the tumor cells abrogated their tumorigenicity and induced a long-lasting protective immune response against a challenge with a tumorigenic dose of parental CMS-5 cells. Co-injection of IL-2-producing CMS-5 cells with unmodified tumor cells inhibited tumor formation even when highly tumorigenic doses of CMS-5 cells were used. Cytolytic activity in mice injected with parental CMS-5 cells was transient and was greatly diminished 3 wk after injection, as commonly observed in tumor-bearing animals. However, in mice injected with IL-2-producing cells, tumor-specific cytolytic activity persisted at high levels for the duration of the observation period (at least 75 d). High levels of tumor-specific cytolytic activity could also be detected in parental CMS-5 tumor-bearing animals 18 d after inoculation with tumor cells, if IL-2-producing CMS-5 cells but not unmodified parental tumor cells were used as targets. These studies highlight the potential advantages of localized secretion of cytokines mediated via gene transfer to induce potent anti-tumor immune responses.

UR - http://www.scopus.com/inward/record.url?scp=0025000864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025000864&partnerID=8YFLogxK

M3 - Article

C2 - 2212951

AN - SCOPUS:0025000864

VL - 172

SP - 1217

EP - 1224

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 4

ER -